Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.37 |
| ▸ | BCL9 | O00512 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69952 | 0.88 | SCD (0.42) | SCDP2RY12BCL9CTNNB1 | |
| SCHEMBL69386 | 0.88 | SCD (0.41) | SCDP2RY12SCD5SMN1; SMN2CYP3A4 | |
| SCHEMBL70664 | 0.86 | SCD (0.46) | SCDP2RY12SCD5SMN1; SMN2CYP3A4 | |
| SCHEMBL91514 | 0.85 | SCD (0.38) | SCDP2RY12SCD5CNR1SMN1; SMN2 | |
| SCHEMBL70545 | 0.83 | SCD (0.45) | SCDP2RY12 | |
| SCHEMBL69558 | 0.82 | EPHX2 (0.47) | SCDP2RY12SCD5SMN1; SMN2 | |
| SCHEMBL29385670 | 0.82 | EPHX2 (0.47) | SCDP2RY12SCD5SMN1; SMN2 | |
| SCHEMBL69931 | 0.82 | EPHX2 (0.47) | SCDP2RY12SCD5CNR1KCNH2 | |
| SCHEMBL70186 | 0.82 | SCD (0.42) | SCDP2RY12SCD5SMN1; SMN2 | |
| SCHEMBL70477 | 0.82 | SCD (0.46) | SCDP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | SCD 1/4885P2RY12 3918/4885BCL9 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.